The Next Decade of Immune Checkpoint Therapy

Sharma, Padmanee, Siddiqui, Bilal A., Anandhan, Swetha, Yadav, Shalini S., Subudhi, Sumit K., Gao, Jianjun, Goswami, Sangeeta, Allison, James P.·2021·Cancer Discovery
DOI 10.1158/2159-8290.cd-20-1680

Cites (229)

Items 201–229 of 229

  1. Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer
    Ruth Perets, Jair Bar, Drew Warren Rasco, Myung‐Ju Ahn, Kiyotaka Yoh, D.-W. Kim, Adnan M. Nagrial, Miyako Satouchi, Daniel Lee, David Robert Spigel et al. · 2020 · Annals of Oncology
  2. Tertiary lymphoid structures associate with tumour stage in urothelial bladder cancer
    Koti, Madhuri, Xu, Amanda Shuo, Ren, Kevin Yi Mi, Visram, Kash, Ren, Runhan, Berman, David M., Siemens, D. Robert · 2017 · Bladder Cancer
  3. Inhibition of aquaporin-1 prevents myocardial remodeling by blocking the transmembrane transport of hydrogen peroxide
    Virginie Montiel, Ramona Bella, Lauriane Y. M. Michel, Hrag Esfahani, Delphine De Mulder, Emma Louise Robinson, Jean-Philippe Deglasse, Malte Tiburcy, Pak Hin Chow, Jean‐Christophe Jonas et al. · 2020 · Science Translational Medicine
  4. Tumor-infiltrating immune cells as potential biomarkers predicting response to treatment and survival in patients with metastatic melanoma receiving ipilimumab therapy
    Balatoni, Tímea, Mohos, Anita, Papp, Eszter, Sebestyén, Tímea, Liszkay, Gabriella, Oláh, Judit, Varga, Anita, Lengyel, Zsuzsanna, Emri, Gabriella, Gaudi, István et al. · 2018 · Cancer Immunology, Immunotherapy
  5. Batf3-Dependent Genes Control Tumor Rejection Induced by Dendritic Cells Independently of Cross-Presentation
    Theisen, Derek J., Ferris, Stephen T., Briseño, Carlos G., Kretzer, Nicole, Iwata, Arifumi, Murphy, Kenneth M., Murphy, Theresa L. · 2019 · Cancer Immunology Research
  6. Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC): Updated analysis of KEYNOTE-426.
    Elizabeth R. Plimack, Brian I. Rini, Viktor P. Stus, Rustem Airatovich Gafanov, Tom Waddell, Dmitry Nosov, Frédéric Pouliot, Denis Soulières, Bohuslav Melichar, Ihor O. Vynnychenko et al. · 2020 · Journal of Clinical Oncology
  7. Abstract CT014: IMbassador250: A phase III trial comparing atezolizumab with enzalutamide vs enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Christopher J. Sweeney, Silke Gillessen, Dana E. Rathkopf et al. · 2020 · Cancer Research
  8. Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance)
    Donna Niedzwiecki, Wendy L. Frankel, Alan Paul Venook, Xing Ye, Paula N. Friedman, Richard M. Goldberg, Robert James Mayer, Thomas A. Colacchio, Jude M. Mulligan, Timothy S. Davison et al. · 2016 · Journal of Clinical Oncology
  9. Immune-Related Adverse Events and Corticosteroid Use for Cancer-Related Symptoms Are Associated With Efficacy in Patients With Non-small Cell Lung Cancer Receiving Anti-PD-(L)1 Blockade Agents
    Mariona Riudavets, Joaquín Mosquera, Rosario García‐Campelo, Jorgina Serra-López, Geòrgia Anguera, Pablo Gallardo, Ivana Sullivan, A. Barba Joaquín, L.P. del Carpio, Agustí Barnadas et al. · 2020 · Frontiers in Oncology
  10. Biomarkers for Response to Immune Checkpoint Blockade
    Ganesan, Shridar, Mehnert, Janice · 2020 · Annual Review of Cancer Biology
  11. LC3-associated phagocytosis (LAP): a potentially influential mediator of efferocytosis-related tumor progression and aggressiveness
    Asare, Patrick F., Roscioli, Eugene, Hurtado, Plinio R., Tran, Hai B., Mah, Chui Yan, Hodge, Sandra · 2020 · Frontiers in Oncology
  12. Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab
    Koichi Sato, Hiroaki Akamatsu, Eriko Murakami, Atsushi Hayata, Nahomi Tokudome, Keiichiro Akamatsu, Yasuhiro Koh, Hiroki Ueda, Masanori Nakanishi, Nobuyuki Yamamoto · 2017 · Annals of Oncology
  13. Immune-related adverse events are associated with improved outcomes in ICI-treated renal cell carcinoma patients.
    Elias, Roy, Yan, Flora, Singla, Nirmish, Levonyack, Nicholas, Formella, Joseph, Christie, Alana, Kapur, Payal, Bowman, Alex Isaac, Hammers, Hans J., Hannan, Raquibul et al. · 2019 · Journal of Clinical Oncology
  14. 879: PD-L1 (B7-H1) Expression by Urothelial Carcinoma of the Bladder and BCG-Induced Granulomata: Associations with Localized Stage Progression
    Brant Allen Inman, Thomas J. Sebo, Xavier Frigola, Haidong Dong, Eric J. Bergstralh, Yves Fradet, Louis Lacombe, Eugene D. Kwon · 2007 · The Journal of Urology
  15. KEYNOTE-756: Randomized, double-blind, phase 3 study of pembrolizumab vs placebo combined with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage estrogen receptor–positive, human epidermal growth factor receptor 2–negative (ER+/HER2−) breast cancer.
    Fátima Cardoso, Aditya Bardia, Fabrice André et al. · 2019 · Journal of Clinical Oncology
  16. A phase III trial of nivolumab with neoadjuvant chemotherapy and adjuvant endocrine therapy in ER+/HER2- primary breast cancer: CheckMate 7FL.
    Sherene Loi, Heather L. McArthur, Nadia Harbeck et al. · 2020 · Journal of Clinical Oncology
  17. Immune-related adverse events and survival in elderly patients with melanoma treated with ipilimumab.
    Mian, Idrees, Yang, Ming, Zhao, Hui, Shah, Mohsin, Diab, Adi, Shannon, Vickie, Patel, Anisha, Amaria, Rodabe Navroze, Giordano, Sharon Hermes, Suarez-Almazor, Maria E. · 2016 · Journal of Clinical Oncology
  18. P1.18-02 The AEGEAN Phase 3 Trial of Neoadjuvant/Adjuvant Durvalumab in Patients with Resectable Stage II/III NSCLC
    John Victor Heymach, Janis Marie Taube, Tetsuya Mitsudomi, David H. Harpole, Michael Aperghis, Leonardo Trani, Mark E. Powell, Phillip A. Dennis, Martin Reck · 2019 · Journal of Thoracic Oncology
  19. Inducible T cell costimulatory (ICOS) receptor agonist, GSK3359609 (GSK609) alone and in combination with pembrolizumab (pembro): Preliminary results from INDUCE-1 expansion cohorts (EC) in head and neck squamous cell carcinoma (HNSCC)
    Danny Rischin, Stefanie L. Groenland, Annette May Ling Lim, Juan Martín-Liberal, V. Moreno, J.M. Trigo Perez, Christophe Le Tourneau, Matthen Mathew, D.C. Cho, Aaron Richard Hansen et al. · 2019 · Annals of Oncology
  20. Checkmate 816: A phase 3, randomized, open-label trial of nivolumab plus ipilimumab vs platinum-doublet chemotherapy as neoadjuvant treatment for early-stage NSCLC.
    Patrick M. Forde, Jamie E. Chaft, Enriqueta Felip et al. · 2017 · Journal of Clinical Oncology
  21. Cancer Imaging in Immunotherapy
    Yousra Eleneen, Rivka R. Colen · 2017 · Advances in experimental medicine and biology
  22. Randomized, double-blind phase 3 study evaluating neoadjuvant platinum-based chemotherapy with perioperative pembrolizumab or placebo in resectable stage IIB or IIIA NSCLC: KEYNOTE-671.
    Hiran Chrishantha Fernando, Jing Liang Yang, Geri L Ferraro · 2018 · Journal of Clinical Oncology
  23. Abstract SY09-01: Next-generation anti-CTLA-4 antibodies
    Alan J. Korman, John Engelhardt, John T. Loffredo, Jose Valle, Rahima Akter, Raja Vuyyuru, Natalie Bezman, Paula So, Robert F. Graziano, Kimberly A. Tipton et al. · 2017 · Cancer Research
  24. Pembrolizumab for metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: updated analysis of KEYNOTE-199
    Antonarakis, Emmanuel S., Goh, Jeffrey C., Gross-Goupil, Marine, Vaishampayan, Ulka N., Piulats, Josep M., De Wit, Ronald, Alanko, Tuomo, Fukasawa, Satoshi, Tabata, Kenichi, Feyerabend, Susan et al. · 2019 · Journal of Clinical Oncology
  25. Genomic correlates of response to immune checkpoint blockade in microsatellite stable solid tumors.
    Natalie I. Vokes, Diana Miao, Claire A. Margolis et al. · 2018 · Journal of Clinical Oncology
  26. A phase 3 randomized study of neoadjuvant chemotherapy (NAC) alone or in combination with nivolumab (NIVO) ± BMS-986205 in cisplatin-eligible muscle invasive bladder cancer (MIBC).
    Guru Sonpavde, Andrea Necchi, Shilpa Gupta et al. · 2019 · Journal of Clinical Oncology
  27. Cancer Imaging in Immunotherapy
    Mira Ayoub, Yousra Eleneen, Rivka R. Colen · 2020 · Advances in experimental medicine and biology
  28. A phase II trial of nivolumab (NIVO) + palbociclib (PAL) + anastrozole (ANA) in postmenopausal women and men with estrogen receptor (ER)+/human epidermal growth factor 2 (HER2)- primary breast cancer (BC): CheckMate 7A8.
    Sara M. Tolaney, Guy Jérusalem, Roberto Salgado · 2020 · Journal of Clinical Oncology
  29. ApricityRx companion digital therapeutic for evidence-based mitigation and phenotype-linked molecular characterization of irAEs in patients receiving immune checkpoint therapy (ICT).
    Matthew T. Campbell, Tian Zhang, Lynda Chin · 2020 · Journal of Clinical Oncology